Ownership Submission
FORM 3
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: January 31, 2005
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  ORBIMED ADVISORS LLC
 2. Date of Event Requiring Statement (Month/Day/Year)
09/14/2004		 3. Issuer Name and Ticker or Trading Symbol
AVANIR PHARMACEUTICALS [AVN]
(Last)
(First)
(Middle)
767 THIRD AVENUE, 30TH FLOOR		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
__X__ Director _____ 10% Owner
_____ Officer (give title below) _____ Other (specify below)
5. If Amendment, Date Original Filed(Month/Day/Year)
(Street)

NEW YORK, NY 10017		 6. Individual or Joint/Group Filing(Check Applicable Line)
___ Form filed by One Reporting Person
_X_ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4)		 2. Amount of Securities Beneficially Owned
(Instr. 4)		 3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5)		 4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Common Stock $ 7,875,002 (2)
I
FN 1 and 3 (1) (3)

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4)		 2. Date Exercisable and Expiration Date
(Month/Day/Year)		 3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4)		 4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5)		 6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
ORBIMED ADVISORS LLC
767 THIRD AVENUE
30TH FLOOR
NEW YORK, NY 10017		   X      
ISALY SAMUEL D
767 THIRD AVENUE, 30TH FLOOR
NEW YORK, NY 10017		   X      
ORBIMED CAPITAL II LLC
767 THIRD AVENUE
30TH FLOOR
NEW YORK, NY 10017		   X      

Signatures

/s/ Samuel D. Isaly 02/17/2006
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Samuel D. Isaly, a natural person, owns controlling interest in OrbiMed Advisors LLC and OrbiMed Capital II LLC. OrbiMed Capital II LLC is the General Partner of Caduceus Private Investments II LP and Caduceus Private Investments II (QP), LP. OrbiMed Advisors LLC is a member of the Managing Member of UBS Juniper Crossover Fund, L.L.C. The reporting persons currently may be deemed to be a director of the issuer by virtue of their having nominated a representative to serve on the issuer's board of directors. Jonathan Todd Silverstein currently serves as the reporting persons' representative on the issuer's board.
(2) Caduceus Private Investments II L.P. owns 5,255,689 shares AVN; Caduceus Private Investments II (QP), LP owns 1,967,838 shares AVN; and UBS Juniper Crossover Fund, L.L.C. owns 651,473 shares of AVN.
(3) The reporting persons disclaim beneficial ownership except to the extent of their pecuniary interest. The report shall not be deemed an admission that the reporting persons are beneficial owners for the purpose of Section 16 of the Exchange Act of 1934, as amended, or for any other purpose.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.